DiffronC therapy (Regen Biopharma Inc)

N/A

Report date: 2024/09/24 10:49:38

Base Information

Drug NameDiffronC therapy (Regen Biopharma Inc)

Drug Alias NameIn vivo siRNA NR2F6 (Regen Biopharma Inc)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionNR2F6 protein inhibitors

TargetsNR2F6 protein

Therapy Area/IndicationsSolid tumoursMyelodysplastic Syndromes

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRegen Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegen Biopharma Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursMyelodysplastic Syndromes

Inactive IndicationsN/A

Other Information

ATC CodeN/A